The perils of buying expensive capital medical equipment from companies in poor financial health were brought into focus last month after the Food and Drug Administration announced the failure of a gamma camera manufactured by Park Medical Systems, which
The perils of buying expensive capital medical equipment from companies in poor financial health were brought into focus last month after the Food and Drug Administration announced the failure of a gamma camera manufactured by Park Medical Systems, which went out of business last year.
According to the FDA, a stainless steel plate from a harmonic drive motor on an Isocam II camera failed, causing an arm of the dual-head system to fall into the gantry housing of the device. No collimator was on the camera at the time and no patient or operator was injured.
Adverse events such as the Isocam II failure are usually reported to the device manufacturer, but since Park filed for bankruptcy last year, the FDA is advising owners of Park systems to report any adverse events due to device malfunction to the agency itself. The FDA is also asking owners of Park systems to notify the agency so it can forward new information to Park users. The FDA's contact on the Park issue is Paula Simenauer, who can be reached by fax at 301/594-2968 or by e-mail at pzs@cdrh.fda.gov.
Park filed for bankruptcy in July after struggling to stay afloat for much of 1997 (SCAN 8/6/97), and the status of much of the company's installed base regarding service and maintenance issues is unknown. At least one Park facility, however, Cedars-Sinai Medical Center in Los Angeles, is using the multivendor service operations of ADAC Laboratories to maintain its system. Cedars-Sinai signed on with ADAC six months ago, according to a hospital spokesperson.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.